Investigational Drug Information for Eritoran
✉ Email this page to a colleague
What is the development status for investigational drug Eritoran?
Eritoran is an investigational drug.
There have been 5 clinical trials for Eritoran.
The most recent clinical trial was a Phase 3 trial, which was initiated on April 11th 2016.
The most common disease conditions in clinical trials are Insulin Resistance, Hypersensitivity, and Toxemia. The leading clinical trial sponsors are Eisai Inc., The University of Texas Health Science Center at San Antonio, and UMC Utrecht.
There are thirty US patents protecting this investigational drug and seven hundred and ten international patents.
Summary for Eritoran
| US Patents | 30 |
| International Patents | 710 |
| US Patent Applications | 203 |
| WIPO Patent Applications | 165 |
| Japanese Patent Applications | 64 |
| Clinical Trial Progress | Phase 3 (2016-04-11) |
| Vendors | 10 |
Recent Clinical Trials for Eritoran
| Title | Sponsor | Phase |
|---|---|---|
| Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia | Australian and New Zealand Intensive Care Research Centre | Phase 4 |
| Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia | Berry Consultants | Phase 4 |
| Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia | Global Coalition for Adaptive Research | Phase 4 |
Clinical Trial Summary for Eritoran
Top disease conditions for Eritoran
Top clinical trial sponsors for Eritoran
US Patents for Eritoran
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Eritoran | See Plans and Pricing | Combination therapy for inducing immune response to disease | IBC Pharmaceuticals, Inc. (Morris Plains, NJ) | See Plans and Pricing |
| Eritoran | See Plans and Pricing | Methods for treating renal disease | Beth Israel Deaconess Medical Center, Inc. (Boston, MA) | See Plans and Pricing |
| Eritoran | See Plans and Pricing | Combination therapy with T-cell redirecting bispecific antibodies and checkpoint inhibitors | IBC Pharmaceuticals, Inc. (Morris Plains, NJ) | See Plans and Pricing |
| Eritoran | See Plans and Pricing | Aptamers specific for TLR-4 and uses thereof | APTATARGETS, S.L. (Madrid, ES) | See Plans and Pricing |
| Eritoran | See Plans and Pricing | Anti-PVRIG antibodies and methods of use | Compugen Ltd. (Holon, IL) | See Plans and Pricing |
| Eritoran | See Plans and Pricing | Uses of 6-aminohexanoic acid to manage bleeding conditions | Emory University (Atlanta, GA) | See Plans and Pricing |
| Eritoran | See Plans and Pricing | Combination therapy for inducing immune response to disease | IBC Pharmaceuticals, Inc. (Morris Plains, NJ) | See Plans and Pricing |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Eritoran
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Eritoran | Australia | AU2014228886 | 2033-03-15 | See Plans and Pricing |
| Eritoran | Canada | CA2942514 | 2033-03-15 | See Plans and Pricing |
| Eritoran | European Patent Office | EP2970428 | 2033-03-15 | See Plans and Pricing |
| Eritoran | Hong Kong | HK1220699 | 2033-03-15 | See Plans and Pricing |
| Eritoran | Japan | JP2016516053 | 2033-03-15 | See Plans and Pricing |
| Eritoran | World Intellectual Property Organization (WIPO) | WO2014144686 | 2033-03-15 | See Plans and Pricing |
| Eritoran | Australia | AU2013302696 | 2032-08-14 | See Plans and Pricing |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
